Open Archive TOULOUSE Archive Ouverte (OATAO)
OATAO is an open access repository that collects the work of Toulouse researchers and makes it freely available over the web where possible.

This is an author-deposited version published in: http://oatao.univ-toulouse.fr/
Eprints ID : 18530

To link to this article: DOI:10.1016/j.otsr.2015.10.011
URL: https://doi.org/10.1016/j.otsr.2015.10.011

To cite this version: Accadbled, Franck and Pailhe, Régis and Cavaignac, Étienne and Sales de Gauzy, Jérôme Bone lengthening using fitbone(r) motorized intramedullary nail: the first experience in France. (2016) Orthopaedics & Traumatology: Surgery & Research, vol. 102 (n° 2). pp. 217-222. ISSN 1877-0568

Any correspondence concerning this service should be sent to the repository administrator: staff-oatao@listes-diff.inp-toulouse.fr
Bone lengthening using the Fitbone® motorized intramedullary nail: The first experience in France

F. Accadbled a, R. Pailhé b,*, E. Cavaignac a, J. Sales de Gauzy a

a Service de chirurgie orthopédique, hôpital des Enfants, CHU de Toulouse, 330, avenue de Grande-Bretagne, 31059 Toulouse cedex, France
b Service de chirurgie orthopédique, hôpital Sud, CHU de Grenoble, avenue Kimberley, 38130 Échirolles, France

Keywords:
Motorized nail
Length discrepancy
Bone lengthening
Fitbone®

A B S T R A C T

Introduction: Intramedullary limb lengthening systems include mechanical systems (the Albizzia nail and the ISKD nail) as well as motorized systems with the Fitbone® (Wittenstein, Igersheim, Germany) and the Precice® (Ellipse Technologies, Irvine, CA, USA) nails. We hypothesized that limb lengthening using the Fitbone® nail was reliable, reproducible, and comfortable for the patient.

Patients and methods: Between 2010 and 2013, a prospective single-center, single-operator (FA) study was conducted on patients who had undergone limb lengthening using the Fitbone® nail. The inclusion criteria were length discrepancy of the limbs equal to or greater than 25 mm or a short stature. The exclusion criteria were indications for cosmetic reasons and/or growth plates that were still open. The lengthening parameters were assessed postoperatively and at the last follow-up. Lengthening was considered achieved when the lengthening objective did not differ by more than 5 mm. All complications were noted. A statistical analysis was performed.

Results: Twenty-six Fitbone® nails were implanted in 23 patients, in the femur in 15 cases and the tibia in 11 cases. The patients' mean age was 22.5 years (range: 15–53 years) and the mean follow-up was 3.4 years (range: 2–5.3 years). The limb lengthening targeted was obtained in 23 cases (88%) and the mean lengthening was 45.3 ± 18 mm (range: 20–80 mm). The mean time to healing was 277 ± 167 days (range: 86–638 days). The mean healing index was 73 ± 57 days/cm for the femurs and 83.5 ± 65 days/cm for the tibias. The mean complication rate was 15.4%.

Discussion: This study emphasizes the good short-term results of this motorized intramedullary lengthening system. An evaluation over the longer term and with a higher number of patients remains necessary.

Level of evidence: IV: uncontrolled, prospective, continuous study.

1. Introduction

Bone lengthening of the limbs is a therapeutic challenge encumbered by complications varying from 11% to 50% depending on the study [1]. The intramedullary bone lengthening systems include mechanical systems (the Albizzia® and ISKD® nails) and more recently motorized systems with the Fitbone® (Wittenstein, Igersheim, Germany) and Precice® (Ellipse Technologies, Irvine, CA, USA) nails [2–4]. Use of mechanical intramedullary implants has reduced the rate of septic complications and fractures of the lengthening callus. However, control of the lengthening and the patients' comfort remain problematic [5]. The preliminary results of the Fitbone® system are encouraging and seem to prevent this type of complication [6–8]. However, these results stem from series of cases including fewer than ten patients for the independent studies and are often retrospective. We hypothesized that limb lengthening using the Fitbone® intramedullary nail was a reliable and reproducible technique that was also comfortable for the patient. In this context, the objective of this study was to provide a prospective assessment of the clinical and radiological results of lengthening the lower-limb using the Fitbone®.

2. Material and methods

Between 2010 and 2013, a single-center, single-operator (FA) prospective study was conducted on patients who underwent lower-limb lengthening with the Fitbone® nail. The inclusion criteria were patients presenting length discrepancy of the limbs equal to or greater than 25 mm or a short stature. The exclusion criteria...
were lower-limb lengthening for cosmetic reasons and/or growth plates that were still open.

2.1. Surgical technique

The patients underwent preoperative planning with the reverse planning method described by Baumgart [9] based on a long leg film taken by EOS® low-dose radiography. Limb length discrepancy and the correction objective in the three dimensions were precisely defined. This also made it possible to define the level of the osteotomy line, distal metaphyseal for the femur and proximal metaphyseal for the tibia, as well as the implant position. Placement of blocking screws was planned if necessary. The patient was installed on a standard orthopaedic table on a plexiglas plate equipped with a metallic grid so as to evaluate the mechanical axis of the operated limb intraoperatively. Intramedullary reaming was performed through a metal working tube, thus preventing debris of the operated limb intraoperatively. Intramedullary reaming was equipped with a metallic grid so as to evaluate the mechanical axis of the operated limb. The nail was connected to a receptor by a wire positioned subcutaneously. The mechatronic implant was installed on a standard orthopaedic table on a plexiglas plate equipped with a metallic grid so as to evaluate the mechanical axis of the operated limb. The osteotomy was performed percutaneously with a 4-mm drill and then an osteotome according to the postage-stamp technique. The nail was connected to a receptor by a wire positioned subcutaneously. The mechatronic implant used, CE marked TAA® (telescope active actuator), can be used on the tibia or the femur either retrograde or antegrade. It is available in 11- and 13-mm diameters with a lengthening capacity up to 8 cm. The patients were not immobilized. Physical therapy was begun the day after surgery. The patient carried out the lengthening with an external transcutaneous command (Fig. 1) in three sessions per day corresponding to 1 mm of distraction.

2.2. Follow-up

The patients were followed-up weekly during the distraction phase during which partial weightbearing (20 kg) and immediate mobilization were authorized. Weightbearing was increased monthly depending on the progression of the callous. Finally, the patients were seen 6 months after implant removal.

2.2.1. Preoperative

The general data collected before surgery comprised age, gender, the surgical site, etiology, the procedures correcting the associated deformity, as well as the lengthening objective. The radiological LDFA (lateral distal femoral angle) and MPTA (medial proximal tibial angle) angles were also measured.

2.2.2. Postoperative

The lengthening parameters assessed postoperatively were the lengthening achieved, the duration of distraction (days), the distraction index (mm/day), the maturation index (days/cm), the healing index (days/cm), the length of the hospital stay (days), joint range of movement of the lower-limb at the last follow-up, return to weightbearing, and return to walking unassisted and with complete weightbearing (Fig. 2). The lengthening was considered achieved when it did not differ by more than 5 mm from the initial objective. Bone healing was defined by corticalization of at least three sides of the callous on AP and lateral X-rays. Patient comfort during the distraction phase was evaluated using a Visual Analog Scale (VAS) and pain was scored from 0 to 10.

The Paley functional score was used for femur and tibial lengthening [10].

The postoperative LDFA and MPTA angles were also measured to assess the correction of the deformities in the frontal plane. Intraoperative and postoperative complications were recorded, as was material removal. The complications were classified according to the Lascombes classification [11] and according to the Paley classification as a simple problem (grade 1), an obstacle (grade 2), and minor or major complications (grade 3) [12].

2.3. Statistical analysis

The descriptive analysis was performed after having verified the Gaussian distribution of the continuous variables. Chi² tests were carried out for the qualitative variables. The subgroups were compared using Fisher exact tests for the quantitative variables and the Mann-Whitney U-test for the qualitative variables. The P-value indicating statistical significance was 5%. The statistical analysis was done using STATA SE v11.0 software (College Station, TX, USA).

3. Results (Table 1)

A total of 26 Fitbone® nails were implanted in 23 patients. In 15 patients, the femur was lengthened and in 11 cases the tibia. The patients’ mean age was 22.5 years (range: 15–53 years) and the mean follow-up was 3.4 years (range: 2–5.3 years). The etiologies requiring the lengthening procedure were congenital in nine cases (34.6%), post-traumatic in 11 cases (42.3%), neurologic in 1 case (3.8%), and post-pandaphysitis during childhood in one case (3.8% At the last follow-up, all the patient’s material had been removed at a mean 20 ± 4.2 months (range: 14–26 months) after it had been implanted. No complications, obstacles, or difficulties were encountered.

3.1. Gain in length

The planned limb lengthening was obtained in 23 cases (88%), for a mean gain of 45.3 ± 18 mm (range: 20–80 mm) (Figs. 3 and 4). Three patients presented a mean 8.6 mm of residual internal limiting membrane (ILM), which was felt clinically by one patient.
3.2. Distraction index and hospital stay duration

Distraction began a mean 7 days after surgery with a mean index of 0.78 ± 0.26 mm/day (range: 0.1–1.32 days) and a mean distraction period lasting 74.1 days (range: 26–421 mm/day). During this period, the mean patient comfort evaluated by the VAS was 2.5 (range: 0–4).

3.3. Maturation (Fig. 5)

There was no statistically significant difference in terms of maturation index according to the different factors studied known to influence the results. The mean duration of maturation was 203 ± 176 days (range: 49–590 days) for the femurs and 259 ± 183 days for the tibias. The mean maturation index was 59.9 ± 59.3 days/cm for femurs and 72.9 ± 69.3 days/cm for tibias.

3.4. Healing (Fig. 5)

The mean healing index was 73 ± 57 days/cm for femurs and 83.5 ± 65 days/cm for tibias. No statistically significant difference was found between tibias and femurs. Similarly, no statistically significant difference was found between patients presenting a preoperative frontal deformity and the others.

3.5. Correction of the deformity

In 11 cases, the axis deformity in the frontal plane was corrected. In patients presenting a frontal mechanical axis deformity, the

Table 1
Radiological results and the incomplete lengthening index.

<table>
<thead>
<tr>
<th></th>
<th>Minimum</th>
<th>Maximum</th>
<th>Mean</th>
<th>Standard deviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Target lengthening (mm)</td>
<td>25</td>
<td>80</td>
<td>45.1</td>
<td>18.1</td>
</tr>
<tr>
<td>Difference (mm)</td>
<td>5</td>
<td>10</td>
<td>7.50</td>
<td>3.5</td>
</tr>
<tr>
<td>Lengthening achieved (mm)</td>
<td>20</td>
<td>80</td>
<td>43.2</td>
<td>18.1</td>
</tr>
<tr>
<td>Preop right aLDFA (◦)</td>
<td>79.0</td>
<td>102.0</td>
<td>85.7</td>
<td>7.5</td>
</tr>
<tr>
<td>Preop left aLDFA</td>
<td>76.0</td>
<td>92.0</td>
<td>82.8</td>
<td>4.2</td>
</tr>
<tr>
<td>Preop right mMTPA</td>
<td>80.0</td>
<td>101.2</td>
<td>89.3</td>
<td>4.3</td>
</tr>
<tr>
<td>Preop left mMTPA</td>
<td>74.0</td>
<td>92.0</td>
<td>87.2</td>
<td>4.0</td>
</tr>
<tr>
<td>Postop right aLDFA</td>
<td>78.2</td>
<td>88.2</td>
<td>83.0</td>
<td>3.6</td>
</tr>
<tr>
<td>Left postop aLDFA</td>
<td>77.2</td>
<td>86.7</td>
<td>82.1</td>
<td>3.9</td>
</tr>
<tr>
<td>Postop right aMTPA</td>
<td>87.70</td>
<td>95.20</td>
<td>90.9</td>
<td>3.8</td>
</tr>
<tr>
<td>Postop left aMTPA</td>
<td>78.0</td>
<td>88.1</td>
<td>85.1</td>
<td>4.7</td>
</tr>
<tr>
<td>Duration of hospital stay (days)</td>
<td>3</td>
<td>10</td>
<td>5.4</td>
<td>2.2</td>
</tr>
<tr>
<td>Healing index (d/cm)</td>
<td>23.75</td>
<td>185.50</td>
<td>77.3</td>
<td>59.0</td>
</tr>
<tr>
<td>Maturation index (d/cm)</td>
<td>11.38</td>
<td>168.00</td>
<td>65.1</td>
<td>61.4</td>
</tr>
<tr>
<td>Distraction index (mm/d)</td>
<td>.10</td>
<td>1.32</td>
<td>0.7</td>
<td>0.2</td>
</tr>
<tr>
<td>Duration of distraction (days)</td>
<td>26</td>
<td>421</td>
<td>74.1</td>
<td>89.5</td>
</tr>
<tr>
<td>Duration of maturation (days)</td>
<td>49</td>
<td>590</td>
<td>225.4</td>
<td>175.0</td>
</tr>
<tr>
<td>Duration of healing (days)</td>
<td>86</td>
<td>638</td>
<td>277.2</td>
<td>167.0</td>
</tr>
<tr>
<td>Time to total weightbearing (days)</td>
<td>58</td>
<td>305</td>
<td>178.5</td>
<td>68.2</td>
</tr>
<tr>
<td>Time to walking (days)</td>
<td>4</td>
<td>229</td>
<td>47.0</td>
<td>54.6</td>
</tr>
</tbody>
</table>

aLDFA: anatomical lateral distal femoral angle; aMTPA: anatomical medial proximal tibial angle.
mean preoperative valgus deviation was $8.7 \pm 5.6^\circ$ (range: 4–15°) versus $3 \pm 1.2^\circ$ (range: 0–5°) postoperatively and the preoperative varus deviation was $13 \pm 8.1^\circ$ (range: 4–20°) versus a postoperative deviation of $2.1 \pm 1.4^\circ$ (range: 0–5°).

3.6. Joint range of movement

The functional results were excellent in 21 patients, good in one case, and poor in one case. The mean functional score was $85.4 \pm 4.3$ (range: 50–100). The knee range of movement was deemed normal in 21 cases; one patient presented a flexion limitation at $70^\circ$ with an extension at $0^\circ$ and another patient flessum at $10^\circ$ with flexion at $140^\circ$.

3.7. Complications

A single intraoperative complication was observed: an inter-condylar fracture during placement of the femoral nail via the retrograde approach. This complication, detected during the intervention, required percutaneous screw fixation (with no consequence on the course of the lengthening procedure).
Postoperatively, according to the Paley classification, in eight patients, five problems were observed (Lascombes grade 1), two obstacles (grade 2), and one major complication (grade 4). The five problems were two postoperative hematomas, two equinus deformities at the end of lengthening, and one complex regional pain syndrome that required physical therapy. One patient presented dysfunctioning of the transmitter allowing the lengthening of the nail, which had to be replaced. One patient having undergone several surgeries presented cutaneous necrosis requiring flap coverage. Finally, one patient decompensated an arteriovenous fistula of the posterior tibial artery during tibial lengthening and an embolization procedure had to be performed.

4. Discussion

This study highlights the good results of the Fitbone® lower-limb lengthening technique with 88% reliability in terms of obtaining the planned lengthening and a 95% rate of good or excellent functional results. However, the number of complications remains high with a 15.3% rate.

This study presents a certain number of limitations. First, the number of patients included was limited (23 patients). This study did not include a group of control patients that would have made it possible to compare the results of this bone lengthening technique with conventional techniques. Finally, this study included the technique’s learning curve marked by the occurrence of an intraoperative intercondylar fracture that could probably have been avoided with more experience.

In addition, using an intramedullary nail presents certain technical limitations. To correct the bone length in the three planes, rigid reamers are required, which makes it impossible to follow the line with the least possible resistance and therefore to guide reaming according to the position selected during the planning stage. Thus, considering the minimum diameter of a Fitbone® TAA nail at 11 mm, this was the greatest limitation in the use of this type of system. The need to make the osteotomy line between 7 and 11 cm from the joint space to ensure solid nail locking is also a limitation. Large angular deformities with a center of rotation and angulation (COR) very distant from the osteotomy are also geometric aspects that may make use of the lengthening systems impossible. Finally, preoperative planning requires being highly rigorous and very precise because, contrary to bone lengthening systems using external fixators, no adjustment can be made postoperatively. The use of bone lengthening nails in children remains limited because of the presence of the growth plates, although some authors, in rare cases of children treated for tumors, report no complications when the implant had a smooth coating and was inserted in the central part of the physis [13,14].

The complication rate of bone lengthening procedures according to the length achieved and surgeon experience ranged from 24% to 117% for external fixation [10,12,15,16] and from 11% to 47% for intramedullary lengthening systems [3,17–19]. For external fixators it has been clearly established that the complication rate varies in adults depending on patient age, the length of the procedure, and the number of wires put in place [12,15]. In children, the amount of lengthening does not seem to be a limiting factor, contrary to the correction of an angulation deformity, which seems to worsen the results when it is greater than 30° [20]. Mechanical lengthening nails such as the ISKD® and Albizzia® require rotation movements to lengthen the limb, which can cause pain and discomfort. A considerable number of patients with the Albizzia® nail had to be rehospitalized so that the rotational movements could be done under anesthesia [17,18,21].

The complication rate in series in which the Albizzia® lengthening nail was used vary from 22% to 29% if these cases of mobilization under anesthesia are not taken into account [17,18]. As for the ISKD® nail, the mobilization rate under anesthesia is around 27% and the complication rate varies from 11% to 48% depending on the study [3,19]. The main problem with the ISKD® nail is the absence of reliable control of the lengthening and its speed [22]. Recently, a new lengthening system called the Precice® nail (Ellipse Technologies, Inc, Irvine, CA, USA) was used in a series of 24 patients. Compared to the mechanical systems, this system presents the advantage of controlling lengthening with an electromagnetic system. However, other than a high material breakage rate (4%), the lengthening procedures require being supervised by the surgeon, which is a significant deterrent to its use [23]. Moreover, the instrumentation of this implant does not include a system of working tubes guaranteeing a minimally invasive implantation and uses flexible reamers for a straight implant, which remains debatable.

Our complication rate with the Fitbone® nail was 15.4%, slightly higher than what has been reported in the literature. Krieg et al. [6] reported a 12.5% complication rate, while Baumgart et al. [7] reported a 13% complication rate in a large series of 150 patients. These low complication rates can be explained in part by controlled and progressive lengthening procedures. In addition, technical complications or material failure seem to be rare events with the Fitbone® nail, in both our experience and the studies reported in the literature [8,24–26]. Baumgart et al. reported a 6% rate of technical incidents and a material failure rate of 3% [7]. We observed no loss of lengthening related to telescoping of the nail or fracture of the locking screws, but Krieg et al. [6] report three incidents of this type. It should be noted that in their study Krieg et al. [6] used the first generation of the Fitbone® nail, which did not provide an anti-telescoping component.

As for bone healing, intramedullary lengthening systems do not seem to disturb bone formation at the lengthening callus. Ilizarov emphasized the importance of preserving endosteal vascularization for osteogenesis of the distraction calluses during lengthening procedures using external fixators [27–29]. Donnan et al. [20] reported a mean healing index of 43.6 days/cm in children treated with external fixators. The Albizzia nail is reported to present a more rapid healing index of 35.2 days/cm [17] and the ISKD nail an index varying from 21 to 29 days/cm [19,30]. For the Fitbone® nail, the healing indices reported range from 48 days/cm to 26 days/cm [6,7]. The slowest indices are observed in particular for the lengthening procedures involving the tibia [7]. The present study found a mean healing index of 73 days/cm for femurs and 83.5 days/cm for tibias. This difference compared to the data reported in the literature can be explained partly by the fact that the mean age of our patients was much older than the age of patients in the other studies, which investigated mainly adolescents and young adults. In addition, the mean target lengthening in the present series was much longer than in other studies.

The short hospital stay and the rapid return to walking are important aspects arguing in favor of the Fitbone® long-bone lengthening systems. The absence of wires transfixing the muscles and skin make early rehabilitation possible during the distraction phase. In addition, during this phase patients can resume partial weightbearing at 20 kg and be mobilized immediately. Weight-bearing is increased monthly depending on the progression of the callus. These advantages are to be compared to the restrictions of external fixators, a source of discomfort related to bone wire care, clothing restrictions, and pain related to the transfixing wires, reducing mobilization and in the end the return to daily and occupational activities [5,31,32].

In conclusion, this study demonstrates the good short-term results with the Fitbone® nail from both reliability and clinical points of view. Assessment on a larger group of patients remains necessary but limited by the cost of this type of device.
Disclosure of interest

The authors declare that they have no competing interest.

References


[20] The authors declare that they have no competing interest.